Published in Monoclon Antib Immunodiagn Immunother on March 14, 2016
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science (1991) 5.14
Mutation in the structural gene for diphtheria toxin carried by temperate phage . Nat New Biol (1971) 4.67
Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell (1992) 3.81
Diphtheria toxin and related proteins. I. Isolation and properties of mutant proteins serologically related to diphtheria toxin. J Biol Chem (1973) 3.78
Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem (1992) 2.37
Heparin-binding EGF-like growth factor. Biochim Biophys Acta (1997) 2.19
Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem (1995) 2.09
Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J (1997) 2.02
The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol (1995) 1.99
Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res (2005) 1.99
Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol Biol Cell (1995) 1.96
Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci (2006) 1.55
Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res (2004) 1.41
Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities. J Cell Biol (2003) 1.36
Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun (2007) 1.27
Contact-dependent growth inhibition and apoptosis of epidermal growth factor (EGF) receptor-expressing cells by the membrane-anchored form of heparin-binding EGF-like growth factor. J Biol Chem (1999) 1.21
Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene (2006) 1.13
Crystal structure of the complex of diphtheria toxin with an extracellular fragment of its receptor. Mol Cell (1997) 1.10
The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin Cancer Res (2011) 1.08
Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer (1996) 1.03
HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers. Cancer Res (2011) 1.01
Membrane type 1-matrix metalloproteinase cleaves off the NH2-terminal portion of heparin-binding epidermal growth factor and converts it into a heparin-independent growth factor. Cancer Res (2010) 0.95
Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. Gastroenterology (1994) 0.95
A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells. Clin Cancer Res (2011) 0.93
Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells. Cancer Sci (2010) 0.92
Anti-human HB-EGF monoclonal antibodies inhibiting ectodomain shedding of HB-EGF and diphtheria toxin binding. J Biochem (2010) 0.89
HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer. Anticancer Res (2010) 0.89
Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy. Anticancer Res (2014) 0.80
Expression of heparin-binding epidermal growth factor-like growth factor in breast carcinoma. Breast Cancer Res Treat (2001) 0.80
Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers. PLoS One (2014) 0.80
Expression of heparin-binding epidermal growth factor-like growth factor in pancreatic adenocarcinoma. Int J Pancreatol (2001) 0.78
Bimodal expression of heparin-binding EGF-like growth factor in colonic neoplasms. Anticancer Res (2001) 0.77
Site-directed mutagenesis of heparin-binding EGF-like growth factor (HB-EGF): analysis of O-glycosylation sites and properties. Growth Factors (2001) 0.76